BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3923750)

  • 1. Involvement of complement in atopic dermatitis.
    Kapp A; Schöpf E
    Acta Derm Venereol Suppl (Stockh); 1985; 114():152-4. PubMed ID: 3923750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of complement in psoriasis and atopic dermatitis--measurement of C3a and C5a, C3, C4 and C1 inactivator.
    Kapp A; Wokalek H; Schöpf E
    Arch Dermatol Res; 1985; 277(5):359-61. PubMed ID: 3875319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3, C5 components and C3a, C4a, and C5a fragments of the complement system.
    Janatova J
    Methods Enzymol; 1988; 162():579-625. PubMed ID: 3265757
    [No Abstract]   [Full Text] [Related]  

  • 5. Anaphylatoxin generation in multisystem organ failure.
    Heideman M; Hugli TE
    J Trauma; 1984 Dec; 24(12):1038-43. PubMed ID: 6334754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation during storage of whole blood, red cells, plasma, and buffy coat.
    Hyllner M; Arnestad JP; Bengtson JP; Rydberg L; Bengtsson A
    Transfusion; 1997 Mar; 37(3):264-8. PubMed ID: 9122898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
    Hack CE; Nuijens JH; Felt-Bersma RJ; Schreuder WO; Eerenberg-Belmer AJ; Paardekooper J; Bronsveld W; Thijs LG
    Am J Med; 1989 Jan; 86(1):20-6. PubMed ID: 2783358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses.
    Takematsu H; Ohkohchi K; Tagami H
    Br J Dermatol; 1986 Jan; 114(1):1-6. PubMed ID: 3484631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement profile in a C1 inhibitor deficient family.
    Sayama K; Shiraishi S; Miki Y
    Br J Dermatol; 1985 Dec; 113(6):737-43. PubMed ID: 4096884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.
    Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S
    Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of three separate anaphylatoxins from complement-activated human serum.
    Hugli TE; Gerard C; Kawahara M; Scheetz ME; Barton R; Briggs S; Koppel G; Russell S
    Mol Cell Biochem; 1981 Dec; 41():59-66. PubMed ID: 6977086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of the terminal complement complex in patient plasma following acute myocardial infarction.
    Langlois PF; Gawryl MS
    Atherosclerosis; 1988 Mar; 70(1-2):95-105. PubMed ID: 3258520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis.
    Hopkins P; Belmont HM; Buyon J; Philips M; Weissmann G; Abramson SB
    Arthritis Rheum; 1988 May; 31(5):632-41. PubMed ID: 3259882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation produced by biomaterials.
    Chenoweth DE
    Artif Organs; 1988 Dec; 12(6):508-10. PubMed ID: 3265053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Activity of total complement and concentration of its components C1q, C3, C4 and C1-inactivator in cancer].
    Matoses Cuquerella S; O'Connor Miquel C; Lluch Hernández AM; García-Conde Bru J
    Med Clin (Barc); 1988 Dec; 91(20):769-74. PubMed ID: 3266280
    [No Abstract]   [Full Text] [Related]  

  • 17. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
    Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
    J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement levels of C4, C3C, factor B, and C1 inactivator in peripheral and retroplacental blood of parturient women with EPH gestosis.
    Zdanowicz A; Jabłońska E; Pietruska Z; Bielecki M
    Ann Med Univ Bialyst Pol; 1993; 38(1):60-7. PubMed ID: 7922487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation during liver transplantation.
    Tomasdottir H; Henriksson BA; Bengtson JP; Bengtsson A; Stenqvist O; Persson H
    Transplantation; 1993 Apr; 55(4):799-802. PubMed ID: 8475554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered concentrations of terminal complement complexes, anaphylatoxins, and leukotrienes in the coronary sinus during cardiopulmonary bypass.
    Bengtson A; Millocco I; Heideman M; Berggren H
    J Cardiothorac Anesth; 1989 Jun; 3(3):305-10. PubMed ID: 2520655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.